Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-422.28%
operating margin TTM
-315.84%
revenue TTM
912.34 Thousand
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -5.65 |
| peg ratio | -0.40 |
| price to book ratio | -3.76 |
| price to sales ratio | 24.79 |
| enterprise value multiple | -10.48 |
| price fair value | -3.76 |
profitability ratios | |
|---|---|
| gross profit margin | 99.55% |
| operating profit margin | -315.84% |
| pretax profit margin | -422.0% |
| net profit margin | -422.28% |
| return on assets | -67.17% |
| return on equity | 64.12% |
| return on capital employed | -56.46% |
liquidity ratios | |
|---|---|
| current ratio | 5.77 |
| quick ratio | 5.65 |
| cash ratio | 1.05 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 6,594.60 |
| operating cycle | 6,736.15 |
| days of payables outstanding | 5,679.64 |
| cash conversion cycle | 1,056.51 |
| receivables turnover | 2.58 |
| payables turnover | 0.06 |
| inventory turnover | 0.06 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | -0.08 |
| long term debt to capitalization | -0.07 |
| total debt to capitalization | -0.09 |
| interest coverage | -3.26 |
| cash flow to debt ratio | -7.71 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.34 |
| cash per share | 0.27 |
| operating cash flow per share | -0.34 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -7.71 |
| short term coverage ratios | -43.70 |
| capital expenditure coverage ratio | -63.26 |
Frequently Asked Questions
When was the last time ImmunityBio, Inc. (NASDAQ:IBRX) reported earnings?
ImmunityBio, Inc. (IBRX) published its most recent earnings results on 05-11-2025.
What is ImmunityBio, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. ImmunityBio, Inc. (NASDAQ:IBRX)'s trailing twelve months ROE is 64.12%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. ImmunityBio, Inc. (IBRX) currently has a ROA of -67.17%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IBRX's net profit margin stand at?
IBRX reported a profit margin of -422.28% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IBRX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 5.77 in the most recent quarter. The quick ratio stood at 5.65, with a Debt/Eq ratio of -0.08.